Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Uri Weinberg appointed Chief Medical Officer while retaining Chief Innovation Officer role.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Uri Weinberg appointed Chief Medical Officer while retaining Chief Innovation Officer role
- Monthly salary increased CHF 5,000 while he remains Chief Medical Officer
- Expanded responsibilities signal added importance of medical and innovation leadership
- Compensation amendment effective April 8, 2026, under affiliate letter agreement dated April 7, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.